Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ranolazine in IBS-D
NCT02239926Phase 3Terminated
- Sponsor
- Mayo Clinic
- Start
- Sep 2014
- Primary completion
- Sep 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of ranolazine in Irritable bowel syndrome with diarrhea (IBS-D), sponsored by Mayo Clinic. Started Sep 2014; status: terminated.
02
Drugs
ranolazine
03
Conditions
Irritable bowel syndrome with diarrhea (IBS-D)
Beyond the preview
Go deeper on NCT02239926.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02239926.